AVCNF Avicanna Inc
Avicanna Inc., a biopharmaceutical company, focuses on the research, development, cultivation, manufacture, and commercialization of plant-derived cannabinoid-based products and extracts for the use in medical, consumer health, and pharmaceutical industries internationally. The company provides pharmaceutical grade cannabinoids, including tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), and other rare cannabinoids; active pharmaceutical ingredients (APIs); feminized seeds; and bulk formulations under the Aureus Santa Marta brand. It also offers CBD based derma-cosmetic consumer products, such as beauty treatment, moisture and protection, and specialized care products under the Pura Earth brand; and medical cannabis/phyto-therapeutic products for the medical or homeopathic use under the Rho Phyto brand. In addition, the company provides pharmaceutical products focusing on skin disorders, including epidermolysis bullosa, eczema, and general skin problems comprising acne, erythema, and dryness; and neurological disorders, such as neuropathic pain, epilepsy, Parkinson's disease and multiple sclerosis, and nociceptive pain resulting from inflammatory and joint disorders, as well as a topical cream for rare genetic skin disorders. Avicanna Inc.was founded in 2016 and is headquartered in Toronto, Canada.
Note: This is not a U.S. company, but they cross-list their shares on the U.S. over-the-counter market - see the related symbol CT:AVCN.
$0.44 OTCQX
As of 01/14/2022 OTCMarkets
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Micro cap
GICS sector: Unknown
Industry: Drug Manufacturers—Specialty &
Index country: Canada
Country of incorporation:
IPO date: 09/03/2019
Outstanding shares: 41,271,574
Average volume: 5,676
Market cap: $18,159,493
Current dividend yield: 0.00%
Sedol:
Valuation (See tab for details)
PE ratio: -0.72
PB ratio: 2.97
PS ratio: 12.89
Return on equity: -654.90%
Net income %: -1,420.00%